Spanish drugmaker Zeltia plans to apply for regulatory approval in the U.S. and Europe for Yondelis, an ovarian cancer treatment, after late-stage trials yielded positive results. The drug, developed from a sea squirt found in the Mediterranean and Caribbean, proved more effective in curbing tumor growth when used in combination with Johnson & Johnson's Doxil than treatment with Doxil alone.

Related Summaries